Related Experiment Video

Updated: Apr 6, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.9K

Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid

Koji Tsumagari1, Zakaria Y Abd Elmageed1, Andrew B Sholl2

  • 1Departments of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA; Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA 70112, USA.

Cancer Letters
|July 26, 2015
PubMed

Insights

Combining AZD6244 and Bortezomib shows significant potential for treating thyroid cancer by targeting MAP kinase and NF-κB pathways. This dual therapy effectively inhibits tumor growth and overcomes resistance seen with single-drug treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • MAP kinase (MAPK) and NF-κB signaling pathways are crucial in thyroid cancer development.
  • Targeting these pathways individually has shown limited success in monotherapy.
  • Drug resistance is a significant challenge in thyroid cancer treatment.

Purpose of the Study:

  • To investigate the combined therapeutic efficacy of AZD6244 and Bortezomib in thyroid cancer.
  • To evaluate the impact of dual targeting on tumor growth, cell cycle, apoptosis, and migration.
  • To assess the in vivo effectiveness in a xenograft model.

Main Methods:

  • In vitro assays assessed cell proliferation, apoptosis, migration, and MAPK pathway activation.
  • In vivo studies utilized a thyroid cancer xenograft model.
  • Tumor size, Ki67, and ppRB phosphorylation were analyzed.

Main Results:

  • Combination therapy significantly inhibited cell growth (56%), migration (29%), and induced apoptosis (38%) compared to monotherapy.
  • Dual treatment led to cell cycle arrest, which was not observed with single agents.
  • In vivo, combination therapy reduced tumor size by 94%, significantly outperforming AZD6244 (15%) and Bortezomib (34%).

Conclusions:

  • Combining AZD6244 and Bortezomib offers a potent therapeutic strategy for thyroid cancer.
  • This dual approach effectively overcomes drug resistance associated with monotherapy.
  • Results strongly support the advancement of this combination therapy into clinical trials.
Keywords:
AZD6244BortezomibMAPKNF-κBThyroid cancer

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.4K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.8K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.4K
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
9.1K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.3K
NF-kB-dependent Signaling Pathway02:26

NF-kB-dependent Signaling Pathway

2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K